The RSM-scale: a Pilot Study on a New Specific Scale for Self- and Observer-rated Quality of Life in Patients with Schizophrenia

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2010 Oct 6

PMID 20922485

Citations 7

Authors

M Riedel

I Spellmann

R Schennach-Wolff

M Obermeier

R Musil

Affiliations

Soon will be listed here.

Abstract

Purpose: To develop and evaluate a self- and observer-rating scale on quality of life in patients suffering from schizophrenia with regard to the efficacy of atypical antipsychotics based on different dimensions and to apply within a pilot study.

Methods: Following review of existing scales and a prevalidation phase, the Riedel-Spellmann-Musil (RSM) scale was developed comprising 36 items assigned to different subscales. As reference scales, the Quality of Life Scale (QLS) and the Subjective Well-being Under Neuroleptic Treatment Scale-short version (SWN-K) were performed, psychopathology and adverse events were measured at all visits. Reliability was assessed using Cronbach's alpha, Pearson's correlation coefficients were used to assess construct validity, and Intraclass Correlation Coefficients (ICCs) were used for test-retest reliability. T tests were performed in normal distributed samples; otherwise Wilcoxon tests were used.

Results: One hundred and thirty-six patients were included in the study. Cronbach`s α was 0.917 for the self-rating and 0.915 for the interviewer-rating part. ICCs were >0.70 for all subscales. The self-rating part correlated strongly with the SWN-K and the observer part with the QLS. Changes in psychopathology over the study period and different levels of functioning were detected.

Conclusion: The RSM-scale is a new scale to assess the quality of life in different dimensions of patients with schizophrenia treated with antipsychotics and shows good internal consistency, test-retest reliability, construct and discriminant validity.

Citing Articles

Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes.

Citrome L, Mychaskiw M, Cortez A, Opler M, Sopina L, Kotak S Innov Clin Neurosci. 2023; 20(4-6):14-33.

PMID: 37387708 PMC: 10306372.

Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.

Heres S, Cordes J, Feyerabend S, Schmidt-Kraepelin C, Musil R, Riedel M Schizophr Bull. 2022; 48(6):1273-1283.

PMID: 35857811 PMC: 9673269. DOI: 10.1093/schbul/sbac068.

Scale development: ten main limitations and recommendations to improve future research practices.

Morgado F, Meireles J, Neves C, Amaral A, Ferreira M Psicol Reflex Crit. 2020; 30(1):3.

PMID: 32025957 PMC: 6966966. DOI: 10.1186/s41155-016-0057-1.

Systematic review of global functioning and quality of life in people with psychotic disorders.

Nevarez-Flores A, Sanderson K, Breslin M, Carr V, Morgan V, Neil A Epidemiol Psychiatr Sci. 2018; 28(1):31-44.

PMID: 30270819 PMC: 7179814. DOI: 10.1017/S2045796018000549.

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.

de Bartolomeis A, Fagiolini A, Vaggi M, Vampini C Neuropsychiatr Dis Treat. 2016; 12:99-108.

PMID: 26811682 PMC: 4714729. DOI: 10.2147/NDT.S96214.

References

Kusel Y, Laugharne R, Perrington S, McKendrick J, Stephenson D, Stockton-Henderson J . Measurement of quality of life in schizophrenia: a comparison of two scales. Soc Psychiatry Psychiatr Epidemiol. 2007; 42(10):819-23. DOI: 10.1007/s00127-007-0249-1. View

McHorney C, Ware Jr J, Lu J, Sherbourne C . The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32(1):40-66. DOI: 10.1097/00005650-199401000-00004. View

Moller H . Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry. 2008; 10(1):6-26. DOI: 10.1080/15622970802264606. View

Caron J, Lecomte Y, Stip E, Renaud S . Predictors of quality of life in schizophrenia. Community Ment Health J. 2005; 41(4):399-417. DOI: 10.1007/s10597-005-5077-8. View

van Nieuwenhuizen C, Schene A, Koeter M, Huxley P . The Lancashire Quality of Life Profile: modification and psychometric evaluation. Soc Psychiatry Psychiatr Epidemiol. 2001; 36(1):36-44. DOI: 10.1007/s001270050288. View

Naber D, Moritz S, Lambert M, Pajonk F, Holzbach R, Mass R . Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001; 50(1-2):79-88. DOI: 10.1016/s0920-9964(00)00166-3. View

Malik P . Sexual dysfunction in schizophrenia. Curr Opin Psychiatry. 2007; 20(2):138-42. DOI: 10.1097/YCO.0b013e328017f6c4. View

Alptekin K, Akvardar Y, Akdede B, Dumlu K, Isik D, Pirincci F . Is quality of life associated with cognitive impairment in schizophrenia?. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(2):239-44. DOI: 10.1016/j.pnpbp.2004.11.006. View

Kawata A, Revicki D . Reliability and validity of the social integration survey (SIS) in patients with schizophrenia. Qual Life Res. 2007; 17(1):123-35. DOI: 10.1007/s11136-007-9288-z. View

10.

Fujii D, Wylie A, Nathan J . Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness. Schizophr Res. 2004; 69(1):67-73. DOI: 10.1016/S0920-9964(03)00122-1. View

11.

Meltzer H . Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr. 2004; 9(10 Suppl 11):15-24. DOI: 10.1017/s1092852900025098. View

12.

Gorna K, Jaracz K, Wrzyszczynska L, Rybakowski F . Quality of life and depression in schizophrenic patients. Adv Med Sci. 2008; 52 Suppl 1:108-11. View

13.

Nordt C, Muller B, Rossler W, Lauber C . Predictors and course of vocational status, income, and quality of life in people with severe mental illness: a naturalistic study. Soc Sci Med. 2007; 65(7):1420-9. DOI: 10.1016/j.socscimed.2007.05.024. View

14.

Heider D, Angermeyer M, Winkler I, Schomerus G, Bebbington P, Brugha T . A prospective study of Quality of life in schizophrenia in three European countries. Schizophr Res. 2007; 93(1-3):194-202. DOI: 10.1016/j.schres.2007.03.005. View

15.

Xiang Y, Weng Y, Leung C, Tang W, Ungvari G . Impact of sociodemographic and clinical factors on subjective quality of life in schizophrenia patients in Beijing, China. J Nerv Ment Dis. 2007; 195(10):853-6. DOI: 10.1097/NMD.0b013e3181568347. View

16.

Naber D . A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995; 10 Suppl 3:133-8. View

17.

Browne S . Rehabilitation programmes and quality of life in severe mental illness. Int J Soc Psychiatry. 2000; 45(4):302-9. DOI: 10.1177/002076409904500409. View

18.

Yeung F, Chan S . Clinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong Kong. Qual Life Res. 2006; 15(9):1459-69. DOI: 10.1007/s11136-006-0006-z. View

19.

Puschner B, Born A, Giessler A, Giebler A, Helm H, Leese M . Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study. J Nerv Ment Dis. 2006; 194(10):746-52. DOI: 10.1097/01.nmd.0000243082.75008.e7. View

20.

Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher M . Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry. 2005; 20(5-6):386-94. DOI: 10.1016/j.eurpsy.2005.02.005. View